Brief: Venture Valuation Provides External Valuation Of Xdivane Program
05/05/2026 06:06
May 5 (Reuters) - Xbrane Biopharma AB XBRANE.ST: VALUATION EXPERT VENTURE VALUATION PROVIDES EXTERNAL VALUATION OF XDIVANE PROGRAM VENTURE VALUATION ESTIMATES PRE-TAX NET-PRESENT-VALUE FOR XBRANE AT SEK 4.4 BILLION AT LAUNCH ESTIMATES SEK 9.6 BILLION ACCUMULATED PROFIT SHARING OVER 10 YEARS FROM LAUNCH OPDIVO ESTIMATED TO GENERATE SEK 100 BILLION NET SALES WITH 80% IV FORMULATION Source text: ID:nMFN1J6W48 Further company coverage: XBRANE.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Xbrane Biopharma AB
See all newsBrief: Xbrane Biopharma, JOINN Biologics US Partner To Develop Xdarzane
Brief: Xbrane Gets FDA BsUFA Review Date
Brief: Xbrane, Partner Intas Agree On Revised Financing Arrangement
Brief: Venture Valuation Provides External Valuation Of Xdivane Program
Brief: Xbrane Biopharma Submits BLA To FDA For Lucentis Biosimilar Candidate